Compare Wendys Co (WEN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs Zoetis Inc — how do they compare? Wendys Co trades at $7.61 (market cap $1.50B), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 21.3× Wendys Co's market cap, and Wendys Co pays the higher dividend (7.13%). Which is the better fit depends on your goals.
| WEN | ZTS | |
|---|---|---|
Market Cap | $1.50B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $11.33 | $156.76 |
52-Week Low | $6.17 | $71.91 |
Enterprise Value | $5.31B | $39.24B |
Dividend Yield | 7.13% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's (WEN) trades at $7.63, down 1.68% on the day, with a bullish technical signal from moving averages and recent meme stock momentum. The company shows consistent earnings beats but faces margin pressure, with net income declining from $204M in 2023 to $165M in 2025. Valuation metrics appear attractive with a P/E of 10.2 and P/S of 0.69, while analyst consensus is mixed with a $7.96 price target.
The stock presents a value opportunity with solid dividends and low valuation, but investors face risks from declining profitability, high debt levels, and competitive pressures. Near-term catalysts include Q2 2026 earnings on August 7 and ongoing Project Fresh initiatives, though weak traffic and cost inflation remain headwinds for sustained growth.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
